ANDA 213473, held by Granules India. Methylphenidate Hydrochloride.
As of Nov 20, 2026, ANDA 213473 (Methylphenidate Hydrochloride), held by Granules India, was first approved by FDA on Jul 29, 2020, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2020 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride27MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride36MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride54MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Sep 28, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 28, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 28, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 11, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 22, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 29, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters